Chamath Palihapitiya (Scott Eells/Bloomberg via Getty Images)
A dry-powder lung disease drug and next-gen antibiotics: Two biotechs and an $880M slate of SPACs land on Wall Street with big ideas
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Another couple of biotech companies and four SPACs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
